NCOA2 and posterior cortical atrophy: NCOA2/SRC-2 mRNA levels are elevated in 20% of primary and 63% of metastatic PCA, which are associated with worse recurrent-free survival, whereas sensitivity to bicalutamide can be restored by the genetic KO of SRC-2 [290].